

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**Sisram Medical Ltd**  
**復銳醫療科技有限公司\***  
*(Incorporated in Israel with limited liability)*  
**(Stock Code: 1696)**

**CHANGE OF CHAIRMAN, CHIEF EXECUTIVE OFFICER AND  
AUTHORIZED REPRESENTATIVE,  
REDESIGNATION AND CHANGE OF DIRECTORS, AND  
CHANGE IN COMPOSITION OF THE BOARD COMMITTEES**

The board (the “**Board**”) of directors (“**Director(s)**”) of Sisram Medical Ltd (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces several updates to its Directors and chief executive officer of the Company (“**Chief Executive Officer**”) as set out in this announcement.

The Board announces that, with effect from 1 January 2026,

- Mr. Yi LIU (“**Mr. Liu**”), a current executive Director and the chairman of the Board (“**Chairman**”), will be redesignated as a non-executive Director due to his work assignment in the Group and will step down from his role as the Chairman, the chairman of the nomination committee of the Board (“**Nomination Committee**”), a member of the remuneration committee (“**Remuneration Committee**”) of the Board and an authorised representative of the Company (“**Authorised Representative**”). Mr. Liu would continue to serve as a member of the Nomination Committee;
- (i) Mr. Lior Moshe DAYAN (“**Mr. Dayan**”), a current executive Director and the Chief Executive Officer, will assume the positions of an executive Director, the Chairman, the chairman of the Nomination Committee and an Authorised Representative, and will no longer take the position as the Chief Executive Officer due to work assignment in the Group; (ii) Ms. Rongli FENG, a current non-executive Director, will assume the position of a member of the Remuneration Committee; and (iii) Mr. Chi Fung Leo CHAN, a current independent non-executive Director, will assume the position of a member of the Nomination Committee;
- (i) Mr. Eyal BEN DAVID (“**Mr. Ben David**”), the current President of the International Division of the Group, will assume the position of the Chief Executive Officer, and (ii) Mr. Jiahong LI (“**Mr. Li**”), an executive Director and the chief financial officer of the Company, will also assume the position of the co-chief executive officer of the Company (“**Co-Chief Executive Officer**”);

- Mr. Yifang WU (“**Mr. Wu**”) has tendered his resignation from the position of a non-executive Director of the Company with effect from 1 January 2026 due to his work reassignment. The Board would like to express its gratitude to Mr. Wu for his contribution to the Company during his tenure of service; and
- Ms. Caroline Xiaokui JIN (“**Ms. Jin**”) has been appointed as a non-executive Director with effect from 1 January 2026. The Board would like to extend their warm welcome to Ms. Jin in joining the Board.

**INFORMATION REQUIRED TO BE DISCLOSED PURSUANT TO RULE 13.51(2) OF THE RULES GOVERNING THE LISTING OF SECURITIES ON THE STOCK EXCHANGE OF HONG KONG LIMITED (“LISTING RULES”)**

**Biography of Mr. Liu**

Mr. Liu (劉毅), aged 50, was appointed as the chairman of the Board and an executive Director on 14 April 2016.

Mr. Liu is currently an executive director, and the chief executive officer and president of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\* (上海復星醫藥(集團)股份有限公司) (“**Fosun Pharma**”, together with its subsidiaries, the “**Fosun Pharma Group**”). He also holds directorships and management positions in certain subsidiaries of Fosun Pharma, including serving as a non-executive director of Shanghai Henlius Biotech, Inc.\* (上海復宏漢霖生物技術股份有限公司) (stock code: 02696), a company listed on the Hong Kong Stock Exchange.

Further biographical details of Mr. Liu were set out in the Company’s annual report for the year ended 31 December 2024 which was published on 22 April 2025. Apart from the details disclosed in this announcement, there has been no other change in Mr. Liu’s biographical details as at the date of this announcement.

Save as disclosed above, Mr. Liu does not hold any position with the other members of the Group and did not hold any directorships in other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the three years preceding the date of this announcement, nor does he have any relationship with any other director or senior management of the Company, or substantial or controlling Shareholders.

As at the date of this announcement, within the meaning of Part XV of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong), Mr. Liu is interested in 140,000 ordinary shares of the Company, representing approximately 0.03% of the issued share capital of the Company held in his personal capacity. Save as disclosed above, Mr. Liu does not have any interest in the shares or underlying shares of the Company and its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance.

Mr. Liu has entered into a letter of appointment with the Company for a period commencing from 1 January 2026, and will continue thereafter unless terminated by either party giving to each other three months’ written notice in advance, subject to the provision of retirement and rotation of directors in accordance with the articles of association of the Company (“**Articles**”), in replacement of his existing letter of appointment with the Company which

commenced from 20 August 2023. Pursuant to the Articles, Mr. Liu will hold office as a non-executive Director until the forthcoming annual general meeting of the Company and will then be eligible for re-election at that meeting. Mr. Liu will not receive any emolument from the Company for acting as a non-executive Director.

### **Biography of Mr. Ben David**

Mr. Ben David, aged 45, was appointed the Chief Executive Officer with effect from 1 January 2026. He joined the Group in 2009 and has been serving as President of the International Division since 2024. In this role, he oversees operations across APAC and EMEA. From 2018 to 2023, Mr. Ben David served as Executive Vice President of Global sales of the Group, where he led worldwide sales, service, marketing and clinical operations, implementing innovative strategies that significantly enhanced market share. Prior to this, Mr. Ben David held a series of senior commercial and leadership roles across Latin America, EMEA, and global distribution channels in Alma Lasers Ltd., driving a period of hypergrowth during his tenure. Throughout his career, his leadership has consistently delivered operational excellence, strategic expansion, and sustained global growth.

Mr. Ben David holds a bachelor degree of Science in Industry Engineering and an Executive Master of Business Administration (“MBA”), both from Ben-Gurion University.

Save as disclosed above, Mr. Ben David does not hold any position with the other members of the Group and did not hold any directorships in other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the three years preceding the date of this announcement, nor does he have any relationship with any other director or senior management of the Company, or substantial or controlling shareholders of the Company (“Shareholders”).

As at the date of this announcement, within the meaning of Part XV of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong), Mr. Ben David has personal interests in 91,745 ordinary shares of the Company, representing approximately 0.02% of the issued share capital of the Company held in his personal capacity. Save as disclosed above, Mr. Ben David does not have any interest in the shares or underlying shares of the Company and its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance.

Pursuant to the terms of the letter of appointment entered into between Mr. Ben David and the Company, Mr. Ben David will serve as the Company’s Chief Executive Officer with no fixed term but subject to the terms of his service contract and termination in accordance with the Company’s policies and procedures. He will receive a salary of USD279,403 at annual base and a discretionary bonus to be determined by the Board from the Company for acting as a Chief Executive Officer. Such remuneration was determined by the Board with reference to the recommendations from the Remuneration Committee, after taking into account multiple factors, including his experience, duties, responsibilities, qualifications, the Company’s remuneration policy and the prevailing market conditions.

## **Biography of Mr. Li**

Mr. Li (李家宏), aged 47, was appointed as an executive Director of the Company on 19 March 2025. Mr. Li joined the Group as the chief financial officer of the Company on 29 October 2024, responsible for the Group's financial operation, financing and investment activities. Mr. Li holds a MBA from National University of Singapore and a Bachelor of Economics from University of International Business & Economics, the People's Republic of China ("China"). Mr. Li is a Certified Management Accountant of the United States, a Chartered Global Management Accountant and a fellow of the Chartered Institute of Management Accountants of the United Kingdom, the Institute of Public Accountant of Australia, and the Institute of Financial Accountants of the United Kingdom. He has over 25 years of experience in financial management, strategy formulation and execution, and M&A gained from Fortune 500 multinational and leading start-up companies in Telecom, Consumer Care and Healthcare industry. Prior to joining the Group, Mr. Li was the executive director, vice president and head of finance and government affairs of EdiGene Inc. from 2021 to 2024, the chief financial officer of Varian Medical Systems Asia Pacific from 2013 to 2021, the regional finance controller of Johnson & Johnson Asia Pacific from 2010 to 2013 and served various financial roles at Motorola across China, Singapore and the United States from 2000 to 2010.

Save as disclosed above, Mr. Li does not hold any position with the other members of the Group and did not hold any directorships in other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the three years preceding the date of this announcement, nor does he have any relationship with any other director or senior management of the Company, or substantial or controlling Shareholders.

As at the date of this announcement, Mr. Li does not have any interest in the shares or underlying shares of the Company and its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance.

Pursuant to the terms of the letter of appointment entered into between Mr. Li and the Company, Mr. Li will serve as the Company's Co-Chief Executive Officer with no fixed term but subject to the terms of his service contract and termination in accordance with the Company's policies and procedures. He will receive a salary of RMB1,260,000 at annual base from the Company and a discretionary bonus to be determined by the Board for acting as a Co-Chief Executive Officer. Such remuneration was determined by the Board with reference to the recommendations from the Remuneration Committee, after taking into account multiple factors, including his experience, duties, responsibilities, qualifications, the Company's remuneration policy and the prevailing market conditions.

## **Biography of Ms. Jin**

Ms. Jin, aged 62, was appointed as a non-executive Director with effect from 1 January 2026.

Ms. Jin was appointed the global chairman of Breas Medical Holdings AB since November 2022. Prior to joining the Group, Ms. Jin served as the vice president of Jafron Biomedical Co., Ltd. (stock code: 300529.SZ) from July 2021 to October 2022. Ms. Jin also served as the head of Renal Care Services in China in Baxter Asia Pacific from March 2020 to June 2021, as Baxter Healthcare Corporation's global head of Geographic Expansion and Emerging Market Growth for its Acute Therapies global business from August 2017 to March 2020, as the global head of Acute Marketing and Portfolios for its global Acute Renal business from January 2016 to July 2017, during which she also served as the interim head of the Global Business Unit from September 2016 to January 2017 and as the regional marketing head for Baxter Healthcare APAC's Acute Renal business in the Asia Pacific region from May 2013 to December 2015. From 2006 to 2013, Ms. Jin held several managing roles at Becton Dickinson and Company in Asia-Pacific. Between 2000 and 2006, she served as a manager at Bayer HealthCare.

Ms. Jin obtained a Doctor of Philosophy degree in Biochemistry and Biophysics from Oregon State University in the United States in 1993. She attended the Master of Science program at the Graduate School of the Chinese National Academy of Sciences in China in 1986. She also obtained a Bachelor of Science degree in Chemistry and Molecular Biology from Jilin University in China in 1985.

Save as disclosed above, Ms. Jin does not hold any position with the other members of the Group and did not hold any directorships in other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the three years preceding the date of this announcement, nor does she have any relationship with any other director or senior management of the Company, or substantial or controlling Shareholders.

As at the date of this announcement, Ms. Jin does not have any interest in the shares or underlying shares of the Company and its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance.

Ms. Jin has entered into a letter of appointment with the Company for a period commencing from 1 January 2026 and will continue thereafter unless terminated by either party giving to each other three months' written notice in advance, subject to the provision of retirement and rotation of directors in accordance with the Articles. Pursuant to the Articles, Ms. Jin will hold office as a non-executive Director until the forthcoming annual general meeting of the Company and will then be eligible for re-election at that meeting. Ms. Jin will not receive any emolument from the Company for acting as a Director.

Each of Mr. Liu, Mr. Dayan and Mr. Wu confirmed that he has no disagreement with the Board. Save as disclosed above, there is no other matter that needs to be brought to the attention of the Shareholders in connection with the change of Chief Executive Officer and Authorized Representative, the Redesignation and change of Directors, and the change in composition of the Nomination Committees and Remuneration Committee as disclosed in this announcement and there is no other information that should be disclosed pursuant to Rule 13.51(2) of the Listing Rules.

On behalf of the Board  
**Sisram Medical Ltd**  
復銳醫療科技有限公司\*  
**Yi LIU**  
*Chairman*

Hong Kong, 8 December, 2025

*As at the date of this announcement, the board of directors of the Company comprises Mr. Yi LIU, Mr. Lior Moshe DAYAN and Mr. Jiahong LI as executive directors; Mr. Yifang WU and Ms. Rongli FENG as non-executive directors; Mr. Heung Sang Addy FONG, Mr. Chi Fung Leo CHAN, Ms. Jenny CHEN and Mr. Kai Yu Kenneth LIU as independent non-executive directors.*

\* *For identification purpose only*